Aboriginal and Torres Strait Islander adults without risk conditions for pneumococcal disease are recommended to receive:

  • a dose of 13vPCV at age ≥50 years
  • a dose of 23vPPV 12 months later
  • a 2nd dose of 23vPPV at least 5 years later

This is based on: 

  • the increased risk of pneumococcal disease in Aboriginal and Torres Strait Islander adults, compared with non-Indigenous adults
  • the high proportion of invasive pneumococcal disease caused by additional serotypes only in 23vPPV

Aboriginal and Torres Strait Islander adults who have previously received 23vPPV are recommended to receive:

  • 1 dose of 13vPCV 12 months after their last 23vPPV dose
  • 1 dose of 23vPPV 12 months after their 13vPCV dose, or 5 years after their previous 23vPPV dose, whichever is later. If they have already received at least 2 doses of 23vPPV, no further 23vPPV doses are recommended. 

In all these scenarios, the interval between doses of 13vPCV and 23vPPV should be 12 months, but 2–12 months is acceptable. The interval between doses of 23vPPV should be 5 years.

Aboriginal and Torres Strait Islander adults with risk conditions for pneumococcal disease are recommended to receive 1 dose of 13vPCV at diagnosis followed by 2 doses of 23vPPV (see recommendations for people with medical risk factors).

Page history

Last updated: 
27 May 2020
Last reviewed: 
27 May 2020

Definitions

13vPCV
13-valent pneumococcal conjugate vaccine
23vPPV
23-valent pneumococcal polysaccharide vaccine